YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. (Q54573687)

1 June 2018

title

YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. (English)

1 reference

1 June 2018

author name string

Mesut Akarsu

1 reference

1 June 2018

Aylin Sengonul

1 reference

1 June 2018

Ethem Tankurt

1 reference

1 June 2018

Ayca Arzu Sayiner

1 reference

1 June 2018

Omer Topalak

1 reference

1 June 2018

Hale Akpinar

1 reference

1 June 2018

Yusuf Hakan Abacioglu

1 reference

1 June 2018

publication date

1 December 2006

1 reference

1 June 2018

Journal of Gastroenterology and Hepatology

published in

1 reference

1 June 2018

volume

1 reference

1 June 2018

issue

1 reference

1 June 2018

page(s)

1783-1788

1 reference

1 June 2018

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Avoiding false positives with PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

False-positive results and contamination in nucleic acid amplification assays: suggestions for a prevent and destroy strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

S-gene sequences and genotype-related restriction sites in hepatitis B virus carriers in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Treatment of chronic hepatitis B: case selection and duration of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Hepatitis B virus genotyping based on cluster analysis of the region involved in lamivudine resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04567.X

10.1111/J.1440-1746.2006.04567.X

21 January 2018

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018